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Biochemical markers in osteoarthritis are molecules that occur during the phys-
iological cycle of the bone and cartilage matrix, and they can be detected in body
fluids. The most important goal of marker metrology in osteoarthritis is that carti-
lage damage can be recognized at the early stage when it has not yet been detected
radiologically. In addition to early recognition, follow-up of disease activity, deter-
mination of disease severity, prediction of prognosis, and evaluation of response to
treatment are other purposes of marker measurement. Type II collagen is the most
important structural element of joint cartilage and is relatively specific to hyaline
cartilage. The main event in osteoarthritis pathophysiology is the damage of the
Type II collagen network. For this reason, researches aimed at detecting
osteoarthritis-specific and specific biochemical markers have focused on Type II
collagen. CTX-II is currently the most investigated and promising biomarker in
relation to osteoarthritis clinic.
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1. Introduction
Osteoarthritis (OA) is a multifactorial, dynamic disease process characterized by
erosion in the joint cartilage, bone hypertrophy at the joint edges, subchondral
sclerosis, synovial membrane, and biochemical and morphological changes in the
joint capsule. It is more common in the elderly [1].
The diagnosis of OA is classically performed by radiological imaging methods
that support clinical findings. However, primary OA developed without any
trauma, especially those without any traumas, started many years before the radio-
logical findings became evident and the pathology is often not revealed early. The
progression of the disease is often slow and is spread over the years. Radiological
findings in OA can provide indirect information about the cartilage tissue. For this
reason, radiological methods are not sensitive especially in the early stage [2, 3].
Early diagnosis allows the joint to treat OA conservatively without interruption.
Imaging methods in OA provide information about the accumulated image that
already existed in the past, rather than the current assessment of how far the disease
has progressed. Therefore, there is a need for alternative methods that can detect
joint changes in a quantitative, reliable, and sensitive manner. Biochemical markers
can serve this purpose. For this reason, recent research on OA has focused on the
development of disease-specific biochemical markers, with an increasing number of
publications in this area in recent decades [4]. Biochemical markers, which stand
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out among laboratory methods, will be discussed in this section in the context of
recent developments.
A good biochemical marker, which is specific to the disease, reflects the disease
activity at that time, is susceptible to posttreatment changes, predicts the outcome
of the disease, and has knowledge of its metabolism and biological properties [5].
Clinical use of the markers should be based on a number of criteria such as clearance
rates, circadian differences, diet, physical activity, and drug use [6].
Biochemical markers in OA are molecules that occur during the physiological
cycle of the connective tissue matrix and can be detected in body fluids. One of the
most important purposes of biochemical markers measurement in OA is the recog-
nition of cartilage damage at the early stages when it has not yet been detected
radiologically. In addition to early recognition, follow-up of disease activity, deter-
mination of the severity of the disease, prediction of prognosis, and evaluation of
response to treatment are other purposes of marker measurement [7].
Until now, no notable findings of a laboratory for primary OA have been
reported. Routine laboratory tests, including the highly sensitive CRP, cannot pro-
vide definitive information regarding disease activity in OA. Although the quanti-
tative values of CRP may increase in synovitis in case of inflammation, the results
are usually normal. Similarly, the serum levels of antinuclear antibodies, rheuma-
toid factor, and complement components are normal. These laboratory findings are
important in terms of differential diagnosis from other diseases with arthritis and
metabolic disorders [7].
In OA, the synovial fluid is noninflammatory, pale yellow, and brittle. It is
mononuclear cell-weighted, with a small number of leucocytes. The viscosity of the
liquid is normal. Excess synovial fluid may suggest that the course of the disease is
going worse [7].
New diagnostic methods are being developed for early diagnosis since OA has
positive responses to early-stage treatment interventions. Biochemical markers
showing bone and cartilage recurrence in recent years have been shown to be useful
in identifying patients at risk for high joint deterioration [8]. They have also been
reported to be compatible with magnetic resonance (MR) imaging [9, 10]. There is
evidence that these markers can distinguish not only the cartilage surface change in
knee OA but also the specific forms of damage to the bone and the surrounding soft
tissue. For this reason, different combinations of markers may play an important
role in the prognosis of the disease.
Despite the lack of specific laboratory methods in diagnosis, many biomarkers
have been recently developed for the diagnosis and follow-up of OA. The joint is a
complex structure of bone, cartilage, and synovial tissue; for this reason, it is useful
to use the markers of these three constructs when determining the degree of the
degeneration of the insert. The extracellular matrix of bone, cartilage, and synovial
tissues forms mainly collagens. These are Type I (bone and synovium), Type II
(cartilage), and Type III (synovium) collagens. Collagen is found together with
aggrecan and other glycoproteins. The speed of construction and destruction of the
cartilaginous structure is slow, so the cartilaginous structure has a long half-life.
Extracellular matrix, mainly composed of collagen in normal conditions, balances
between construction and continuous renewal. However, when the speed of con-
struction cannot capture the speed of destruction, the cartilaginous structure grad-
ually loses its integrity [11].
In general, cartilage, proenzymes, active proteinases, proteinase inhibitors,
matrix fragments that are released by proteinases, and antibodies developed by
the organism against cartilage components are among the markers of cartilage
cycling in pathologies involving joint cartilage. Among these markers, the pro-
teoglycans most frequently researched are the smaller fragments of the structure
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that eventually result in proteolytic destruction. Knowledge of the biochemistry
and immunological properties of the proteoglycans has allowed the measurement
of proteoglycan components and degradation products with more sensitive
methods [12].
Nowadays, these methods can be used to measure proteoglycan degradation
products in the serum and synovial fluid inflammation and degenerative joint
diseases. Some studies have found that there is a correlation between proteoglycan
levels in the synovial fluid and severity of the disease [12].
Several biochemical markers such as Type II collagen, proteoglycans,
hyaluronan, cartilage oligomeric matrix protein (COMP), and matrix metallopro-
teinases (MMPs) have been investigated in relation to OA and radiological progres-
sion, and frequently conflicting results have been obtained [13].
In some studies with COMP, it was concluded that OA progression was posi-
tively related, while in other studies, it was shown that it was affected by factors
such as age, ethnicity, and BMI (body mass index), which had a weak relationship
with the narrowing of the joint space and disease progression. In addition, it is
reported that cartilage is not specific, and it is also found in structures such as the
synovium and meniscus [14].
Glucosyl-galactosyl-pyridinoline (Gly-Gal-Pyd), Type I, and Type III are cross-
links of the collagenous roof. It is found in the synovial tissue and has been identi-
fied in in vitro studies that have occurred during the cartilage destruction process.
In a study conducted, urinary Gly-Gal-Pyd levels were found to correlate strongly
with pain and disability scores and radiological disease stage in patients with knee
OA [15].
Type II collagen is the most important structural element of the joint cartilage
and is relatively specific to hyaline cartilage. The main event in OA pathophysiology
is the damage in the Type II collagen network. Therefore, investigations aimed at
detecting OA-specific and specific biochemical markers have focused on Type II
collagen [15].
Experimental arthritis models are exploring cartilage metabolism in a variety of
ways. In one study, an increase in synovial fluid proteoglycan fragments in the
experimental OA model showed concordance with the severity of arthritis [12].
The use of biomarkers in OA has some significant purposes. One of these is the
predetermination of patients with rapid cartilage destruction in order to prevent
joint destruction in the future because the period of the radiographic degeneration
of the joints and the diagnosis of OA are usually detected in the advanced stages of
cartilage damage from the molecular point of view. In addition to early recognition,
monitoring of disease activity and determination of disease severity, prediction of
prognosis, and cartilage degradation should be tracked in order to monitor the
efficacy of new drugs developed as cartilage protectants [16].
Some criteria must be considered for a biomarker measurement to be valid in
OA. First of all, it is necessary to know what kind of pathology the specimen
measured reflects since there are different types of markers for tissue damage,
tissue repair, anabolic or catabolic processes, or pathologies at the cell or tissue level.
It is also important that the measured indicator is indeed the marker to be mea-
sured. For this reason, the method should be well investigated and the most appro-
priate method should be selected according to the conditions. Furthermore, the
biomarker measurement results should be compatible with the clinical and radio-
logical findings of the disease and with the pain-function score. It should also reveal
the smallest change in the severity of the disease [16].
In order to understand the clinical benefit of biomarkers, it is necessary to
initially standardize the measurement method used. Sample receipt time, purchase
and storage conditions, and each biomarker circadian rhythm should be known.
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Some may be affected by factors such as physical activity, age, and gender. For
example, C-terminal cross-linked Type II collagen (CTX-II) and serum COMP
(sCOMP) from cartilage markers show very little circadian variation [11].
At the later stages of OA, cartilage damage to the tissue occurs at a high rate,
making it difficult to interpret when the marker is detected at a very low concen-
tration. Serum can change the levels of biomarkers with foods such as hyaluronic
acid. At the first hour after feeding, hyaluronic acid levels reach the highest point.
For this reason, the serum levels of biomarkers in OA should be checked on an
empty stomach. Metabolism of biomarkers, kidney excretion, and drugs can also be
affected. The level of urine CTXII is affected by ibuprofen [11].
The levels of certain biomarkers such as COMP, chondroitin sulfate, and urine
CTX-II may vary with age and sex, as well as joint pathology. In addition, a patient’s
ethnicity and BMI may affect the baseline measurement values of biomarkers. There
are different classifications for biomarkers to be used in OA. These may be direct
and indirect markers, cartilage, bone and synovial tissue, or markers of synthesis
and destruction. It is more accurate to classify OA in comparison to the tissues from
which they originate if the bone and the synovial tissue as well as cartilage are
thought to have contributed to the development and the course of OA [16].
2. Metabolic processes of osteoarthritis during which biomarkers
emerge
In osteoarthritis, significant changes that cause an inflammatory cascade which
in turn triggers the chronic overproduction of factors at the metabolic level occur.
These factors may aggravate osteoarthritis. Biomarkers are metabolic processes of
all kinds which develop during the inflammatory process in osteoarthritis.
Hyaline cartilage structure is principally composed of water, collagen, and pro-
teoglycans, which include sparsely distributed chondrocytes. Chondrocytes provide
a balance between the anabolic and catabolic activities that protect the aggrecan
structure [17]. Deprivation of the cartilaginous matrix results in an imbalance
between the cartilage synthesis (anabolic) and resorption (catabolic) processes in
the joint. Mechanical strain causes upregulation of cytokines like interleukin-1β (IL-
1β) and tumor necrosis factor alpha (TNF-α) with a rapid transcription through a
shock sensor system in chondrocytes and tendons [18]. The mechanical strain
resulting from normal activity or therapeutic exercise in fact inhibits this
upregulation and helps in the remodeling of the cartilage through collagen synthe-
sis. The upregulation of cytokines causes induction of MMPs which enzymatically
disrupts the cartilage structure [19]. In addition, mechanical strains cause
microcellular damage which leads to the release of extracellular membrane particles
and intracellular microtubule elements into the joint [20].
These mechanical strains also produce other metabolic changes such as the
release of arachidonic acid from the phospholipids in the damaged intra-articular
cell membranes after phospholipase A2 (PLA2) action [21]. The continuous strain
together with the metabolic processes causes inflammation in the joint tissues. The
main cytokines that cause degradation in the synovia are the IL-1, IL-6, IL-17, and
TNF-α [22]. Other elements and side products which further increase the cartilage
degradation and play a role in osteoarthritis include insulin-like growth factor 1
(IGF-1), transforming growth factor beta1 (TGF-β1), and chondrodegradative
enzymes [23].
In cases of acute or chronic joint damages, arachidonic acid is the primary fatty
acid produced by the metabolic conversion of the cell membrane phospholipids
through PLA2. Through other enzymatic activities, arachidonic acid transforms into
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various inflammatory mediators such as cytokines and eicosanoids, which lead to a
progression of the disease.
During the metabolic conversion of arachidonic acid into inflammatory metab-
olites, the two most important enzymatic pathways are the 5-lipoxygenase (5-LOX)
and cyclooxygenase (COX) [24]. These parallel pathways produce the leukotrienes,
prostaglandins, thromboxanes, and prostacyclins, which play a significant role in
the onset and progression of the inflammatory response. The conversion of
arachidonic acid through COX-2 leads to production of prostaglandins, which are
physiologically important mediators in tissue repair and prostacyclins [25].
The metabolic transformation of arachidonic acid through 5-LOX, another induc-
ible enzyme, leads to the production of leukotrienes. Leukotriene B4, specifically, is
a chemoattractant and a fatty acid metabolite that causes damage in the cells and
tissues [26]. Leukotrienes initiate the production of new reactive oxygen species. The
upregulation of the inflammatory cascade of cytokines causes permanent disruption
of the cell membrane, thus leading to formation of more arachidonic acid [27].
Matrix metalloproteinases produced from chondrocytes are zinc-containing
proteinases which degrade the cartilage. In particular, the expression of MMP-1 and
MMP-13 is induced by IL-1β, which in turn causes the degradation of Type II
collagen [28].
Chondrocytes also produce the reactive oxygen species. The production of reactive
oxygen species causes damage on the components of the cartilage matrix and induces
apoptosis [29]. Another form of transformation is the nonenzymatic lipid peroxida-
tion of arachidonic acid. When arachidonic acid is exposed to reactive oxygen species,
the molecule is oxidized to three main products: F2-isoprostanes, 4-hydroxynonenal,
and malondialdehyde [30]. All three molecules directly destroy the hyaline cartilage.
Chondrocytes also produce the reactive oxygen species like xanthine-hypoxanthine
system, hydroxyl radicals, peroxide, and hydroxyproline [31].
Each of the biochemical products produced along the sequence of inflammatory
cascade in osteoarthritis mentioned briefly above is investigated as a biochemical marker
in the early diagnosis, during treatment and later during follow-up of the disease.
3. Biochemical markers of bone origin
The bone matrix consists mainly of Type I collagen molecules linked by
pyridinoline (PyD) and deoxypyridinoline (D-PyD) cross-links. The degradation of
Type I collagen can be assessed by pyridinoline cross-links in the urine. NTX-I and
CTX-I, the epitopes of N-terminal and C-terminal cross-link telopeptides, are the
most studied bone resorption markers. Bone formation and degradation markers
shown in Table 1 can be affected by regional subchondral bone structure defects
[32, 33]. Serum and urine concentrations may vary due to age, menopause, osteo-
porosis, and other bone diseases. Bone markers in osteoarthritis give incompatible
results due to several factors that can affect the results.
Bone Production Demolition
Type I collagen N- and C-propeptides (PICP
and PINP)
Pyridinoline (PYD), deoxypyridinoline







Tartrate-resistant acid phosphatase (TRAP)
Table 1.
Biochemical markers of bone origin used in OA.
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Urine C-terminal and Type I collagen telopeptide levels (CTX-I) were higher in
cases with a rapid onset of osteoarthritis than slow-onset events [34]. Bone
sialoprotein (BSP) is a product of active osteoblasts located in the junctions of
mineralized cartilage and subchondral bone tissue. Elevated levels of serum BSP
reflect the bone matrix cycle [35].
There is evidence that combined measurement of COMP and BSP may be a
prognostic marker to determine the development of OA in chronic knee pain cases
[36]. Osteocalcin, an important component of bone noncollagen matrix, is released
during mineralization. This measurement gives information about bone formation.
It is important to demonstrate subchondral bone metabolism [16].
During cartilage damage, changes in the bone metabolism occur and the mole-
cules of the bone increase in body fluids. In general, elevated serum BSP reflects the
bone matrix cycle [33].
Serum and urine levels of bone markers may vary due to menopause, osteopo-
rosis, and other bone diseases. It is an important question in terms of OA perfor-
mance [37].
Bone markers have shown more pronounced circadian rhythm changes and
more concentrated on cartilage and synovial tissue markers in recent years due to
inconsistent results.
3.1 Biochemical markers of cartilage production
The main event in the pathophysiology of OA is the destruction of the Type II
collagen nerve which is formed by COL-2 α1 fibrils. For this reason, OA studies
have focused on Type II collagen. Type II collagen is only 1% of all collagen in the
body, and the normal cycle is slow. Type II collagen, predominantly found in the
joint cartilage, is synthesized procollagen in chondrocytes (Table 2). Subsequently,
the extracellular fluid is released, where the procollagen carboxy-terminal and
amino-terminal propeptides (PIICP and PIINP, respectively) are separated from the
parent construct, and mature collagen synthesis is completed. These are important
indicators of collagen synthesis in the articular cartilage. And the levels of cartilage
tissue, serum, and synovial fluid can be measured [11].
PIICP and PIINP may be the most common Type II collagen [12] in the cartilage
(Table 2). COL-2 molecules are synthesized as propeptides from the carboxy-
terminal and amino-terminal regions of the extracellular domain before forming
fibrils. These peptides are cysteine-rich PIINAP, a prokaryotic Type II C-terminal
propeptide (PIICP), a procollagen Type II N-propeptide (PIINP), and a second
form of PIINP. They are indicators of chondrocyte synthase activity. It has been
detected that serum PIINAP levels are inversely correlated with the loss of cartilage
induced by MR or radiography in patients with OA [38].
Cartilage Production Demolition
Type II collagen N- and C-propeptides
(PIICP, PIIANP, PIIBNP)
PYD, CTX-II
Type II collagen fragments
Aggrecan Chondroitin sulfate epitopes Keratan sulfate epitopes






Biochemical markers of cartilage origin used in OA.
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The development of OA in the synovial fluid of individuals with knee injuries
has reached maximum levels of propeptide levels in the preradiological period [39].
In a study by Garnero, serum PIIANP levels in OA patients showed a decrease
[14]. The increase in the urine CTX-II levels with serum PIIANP levels may indicate
that joint destruction develops more rapidly. PIICP levels give hope to early detec-
tion of OA.
Nine amino acid peptides (COL2-1) and their nitrated form (COL2-1 NO2) of
Type II collagen are localized peptides in the collagen network of the triple helix
structure and show oxidative degradation of this helix structure. In a 3-year follow-
up study in patients with knee OA, it was observed that initial increases in urine
levels were associated with high disability assessed by the Western Ontario and the
McMaster University Osteoarthritis Index (WOMAC) [40]. These results suggest
that the urinary levels of COL2-1 and COL2-1 NO2 may reflect the clinical severity
of OA. However, a significant association of COL2-1 NO2 with CRP and an
increased synovial inflammation requires caution in the differentiation of other
arthritic patients [5].
Another name for YKL-40, a cartilaginous marker, is glycoprotein-39. In
advanced stage OA, serum and synovial fluid are present in high amounts. Elevated
serum levels were detected in hip OA. YKL-40 levels may also increase depending
on other pathologies, especially inflammation. For this reason, inflammation can
also be considered as a marker [41].
3.2 Biochemical markers of cartilage destruction
The most well-known marker in the demolition reagents is COMP. Increasing
levels are thought to indicate that OA is advancing. Since COMP is synthesized not
only by cartilage but also by synovial cells, tendon fibroblasts, and osteoblasts, the
increase may be due to cartilage destruction or synovial inflammation. In the knee
OA, the COMP level is synovitis grade compatible, but it is shown that OA is not
compatible with the grade. The absence of COMP specificity may limit the use of
OA-RA (rheumatoid arthritis) to assess changes in joint damage [42].
4. Type II collagen destruction products
There is a consensus that Type II collagen degradation products can be used as
markers in the diagnosis and follow-up of OA and RA [43]. C2C and C1-2C are new
epitopes formed after destruction of Type II collagen speckle collagenases. For this
reason, it can give opinion on the destruction of cartilage. The levels of C1-2C were
found higher in OA cartilage than in normal cartilaginous tissue [11].
CTX-II is also a Type II collagen degradation product and an important indicator
of cartilage damage. Urine CTX-II levels were elevated in RA and OA, and high
levels were found to be compatible with joint erosion [43]. In patients with knee
OA, urine CTX-II measurement has shown that it may be useful in determining the
prognosis of joint damage, and they have been found useful as a determinant for
rapid degeneration of joint cartilage [44].
In another study, it was determined that the urine CTX-I and CTX-II and
sCOMP levels can determine patients with focal cartilage lesions in the early stages
of knee OA [45]. At the beginning of OA, new epitopes emerged from the triple
helix of collagen collapsed by collagenases. The C-terminal telopeptide, one of these
epitopes, is now the most searched for association with OA clinic and is most
promising as a specific marker for OA [44]. In many studies, OA was found to be
particularly high in urine levels compared to controls and that it can be used as a
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diagnostic marker [46]. Another publication has shown that high CTX-II levels are
associated with radiological progression of the knee and hip in OA and that they
increase eight times the risk of progression in these individuals [44].
Bettica et al. found a relationship between urinary CTX-I and knee OA develop-
ment in terms of cartilage derivation markers [34]. Urine CTX-II has been reported
as a good marker of knee and hip OA progression [47, 48].
5. Oligosaccharides
Chondroitin sulfate and keratan sulfate are oligosaccharides that bind to the
aggrecan protein and are the first molecules in which cartilage formation and degra-
dation are evaluated. The affinities of these oligosaccharides depend on the length
and sulfation of the molecule and thus may vary from person to person. It is present
at high concentration in the circulation during prolonged disease and significant loss
of cartilage. Although cartilage is at the highest concentration in the tissue, chondroi-
tin sulfate and keratan sulfate epitopes can be found in the cartilage as well as in the
extracellular matrix of the molecules outside the acceptor. For these reasons, their use
as a marker in clinical evaluation and treatment follow-up is very limited.
Biglycan, decorin, fibromodulin, and lumican are small leucine-rich proteogly-
cans (SLRPs). The destruction of these small proteoglycans, along with the large
molecule of cartilage-like aggrecan, suggests that it is active OA [11].
6. Biochemical markers of synovial tissue construction
6.1 Hyaluronan
It has been shown that radiological progression is faster in OA patients with high
serum hyaluronan (sHA) levels [49]. It is not useful as a marker in everyday
practice due to its distinctive circadian rhythm [37].
6.2 Highly responsive CRP
Osteoarthritis becomes defective in the chondrocyte metabolism and therefore
there is an increased interest in acute phase proteins in OA, despite a common
systemic manifestation of RA in nature. It has been reported that high-sensitivity
CRP (hs-CRP) levels may be a prognostic feature of rapid progressive hip and knee
OA (Table 3). In a study conducted to investigate the association between hs-CRP
Synovial tissue Production Demolition
Type III collagen Type II N-propeptide (PIINP) PYD, CTX-I, NTX-I
Glucosyl-galactosyl-
pyridinoline (Gly-Gal-Pyd)
Noncollagenous proteins Hyaluronan, YKL-40, COMP
Proteases and inhibitors Tissue matrix proteinases (TIMP 1, 2) Matrix metalloproteinases
(MMP 1, 2, 3, 9)
Systemic infection Highly sensitive CRP
Table 3.
Biochemical markers originating from the synovial tissue used in OA.
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and the OA severity and size in patients with advanced hip and knee OA, the
severity of pain in the advanced OA patient group, although not the extent of OA,
was associated with hs-CRP [50]. In a study designed to determine whether the
levels of IL-6, TNF-α, and CRP in the normal population could be an adjunct marker
in radiographic knee OA, the prevalence and incidence of radiological knee OA and
the circulating levels of IL-6 were found closely related [51].
7. Biochemical markers of synovial tissue demolition
7.1 Matrix metalloproteinases (MMPs)
Matrix metalloproteinases have been measured mainly in studies related to RA.
The metalloproteinase enzyme group may cause collapse of the extracellular matrix
elements by acting as collagen and Type II collagen [10]. The tissue inhibitors of
metalloproteinases (TIMPs), which are natural inhibitors of metalloproteinases, are
released from both chondrocytes and synovial cells. The synovial fluid and serum
MMP-1 and MMP-3 levels have been shown to be elevated in patients with hip or
knee OA. It has been reported that MMP-1 and MMP-3 levels can be detected not
only in RA and OA but also in other adult states such as systemic lupus
erythematosus [52]. MMP-3 has been reported radiographically to predict
narrowing of the joint space [53].
7.2 Glucoside-galactose-pyridinoline
In the extracellular matrix, collagen Type II fibrils are placed in triple alpha
helix. They are present at very low levels in the cartilage and other tissues found
abundantly in the human synovium, thus showing an increase in urine Gly-Gal-Pyd
levels in knee OA [54].
8. Other biochemical markers
Metabolic changes associated with obesity are possible causal agents for OA.
Leptin is released primarily from adipocytes but is also released from chondrocytes
and production increases in the cartilaginous form of OA. Leptin levels in synovial
fluid are a possible metabolic factor in the pathogenesis of OA.
The role of markers such as leptin and IL-6 in obese-associated hip OA is
unclear. In a study, it was determined that metabolic and ambulatory mechanisms
may play a role in the etiology of hip OA and that the relationship between bone
composition and the narrowing hip joint space was mediated by leptin, particularly
in women [53].
Proteomic studies, which reveal the protein content of the cell tissue and bio-
logical fluids, distinguish related proteins and show functional changes in proteins
have become more prominent in recent years [55]. In 2011, studies describing new
proteomes in the urine, serum, and chondrocyte vesicles of OA patients were
published [56]. In one of these studies, two fragments of fibulin-3 (Fib 3-1 and Fib
3-2) were shown to increase in the urine of OA patients.
Fibulin-3 is a proteome closely related to the TIMP, which plays an important
role in the pathogenesis of OA. While it is suggested that they are biomarkers with
high sensitivity and specificity, more work is needed to confirm them [57].
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Deamidated COMP (D-COMP) hip joint was associated with OA radiological
severity, but the same relationship was not detected with knee OA. It was suggested
that D-COMP may be a biomarker specific to the hip joint [58].
It is thought that soluble leptin receptor (sOB-R) may be a marker of cartilage
damage because of the significant relationship between the basal sOB-R level and
low osteocalcin and PIIANP levels [59].
Since sOB-R is an adipokine receptor, it may be a promising marker for clarify-
ing the relationship between obesity and pathogenesis of OA, especially in load-
bearing joints [60].
9. Clinical evaluation of the osteoarthritis biomarkers present
Osteoarthritis Research Society International (OARSI) has published a series of
recommendations for the use of soluble biomarkers in clinical trials. Publications
supported by OARSI summarize the basic steps for a biomarker to be used as a drug
development tool and various situations that OA biomarkers can be used [61, 62].
The Foundation for the National Institutes of Health/Osteoarthritis Initiative
(FNIH/OAI) has published the results of an analysis on soluble biomarkers in a
study that investigated the use of biomarkers as a drug development tool [61, 62].
The FNIH/OAI researchers found that time-dependent concentrations of urine C-
terminal telopeptide of Type II collagen (uCTX-II), sHA, and serum N-terminal
telopeptide of Type I collagen (sNTX-I) over a 24-month period were associated
with subject cases that had both progressive pain and radiographic progression of
knee OA over a 4-year period. Baseline levels of uCTX-II and sNTX-I predicted pain
progression and radiographic progression. Plans are underway to qualify these bio-
markers using samples and data from already-completed DMOAD (disease-
modifying osteoarthritis drugs) trials.
Over the past years, several biomarkers have been tested in samples taken from
patients with OA of various degrees. However, the number of newly found bio-
markers was limited; most of them were already discovered molecules including
MMPs, interleukins, adipokines and joint-related serum biomarkers, MMP-
mediated degradation of C-reactive protein (CRPM), MMP-mediated degradation
of Type III collagen (C3M), cartilage oligomeric matrix protein (COMP), HA
(hyaluronic acid), N-terminal propeptide of collagen IIA (PIIANP), COL2-3/4 C-
terminal cleavage product of Types I and II collagen, uCTX-II, MMP-3, and urine-
nitrated Type II collagen degradation fragments (uCOL2-1 NO2).
The first analytical data came from the OAI. Eighteen biomarkers believed to be
associated with OA were tested in the 129 blood or urine samples collected from OA
patients [61]. The results showed that three commercially available biomarkers
were related to age: sHA, P2ANP, and C1,2C. Similarly, uCTX-II, MMP-3, uCOL2-1
NO2, and sHA showed gender-related differences [61]. In a study, the concentra-
tion levels of sCOMP, sCTX-II, sMMP-3, sPIIINP, and sHA were identified in 79
patients who had cartilage damage and underwent knee arthroscopy or total knee
replacement [63]. PIIANP, serum CTX-II, HA, and COMP levels were measured;
however, only the concentration levels of HA and COMP were found significantly
higher in OA patients with cartilage damage in the early term. These results suggest
that the concentration levels of sCOMP and HAmay be used in predicting the early-
term cartilage lesions in the knee.
In a study on CRP [64], 58 cases of knee OA and 33 controls were examined for
CRP and MMP-derived collagen types C1M, C2M, and C3M. The knee OA cases had
elevated levels of C1M, C2M, and CRP and significantly lower level of C3M in
comparison to controls.
10
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Over the past few years, a limited number of studies have attempted to validate
the existing OA biomarkers in the context of a clinical DMOAD study. Karsdal et al.
[65] studied uCTX-I, uCTX-II, and serum osteocalcin. After 24-months, the bio-
markers declined in all patients who had a positive Western Ontario and McMaster
Universities Arthritis Index (WOMAC) pain response to calcitonin. However, in
another calcitonin study [65], the pain and biomarker responses after 24 months
were not significant and the radiographic responses between the two studies were
also different. This made it difficult to confirm these biomarkers for pain or radio-
graphic response. The authors of the clinical trial of calcitonin have concluded that a
precisely successful DMOAD study will be necessary to confirm the predictive and
surrogate biomarkers for OA drug development.
Researchers have come up with studies that examine large OA cohorts dealing
with the predictive ability of established OA biomarkers [66, 67]. In one of these
studies, the sHA was associated with the joint space width (JSW) in the Iwaki
Health Promotion Project over a period of 5 years [66].
In a Chingford cohort study [67] with a 20-year data history of radiographic
knee OA progression in a group of middle-aged women with a Kellgren and Law-
rence (KL) score of 0 at baseline, the high sCOMP levels were significantly related
to painful radiographic OA development in the knee. The increase in the risk of
radiographic knee OA was found in relation to sCOMP during the 5-year follow-up
of 493 cases. In another report [68], 5 years of data from the Rotterdam study
cohort were used to determine the relationship between the incidence of OA and KL
score progression and biomarkers. As reported by Van Spil et al. [68], uCTX-II and
sCOMP were found to be significantly associated with the incidence and progres-
sion of OA. The researchers investigating the 5-year data from the Cohort Hip and
Cohort Knee (CHECK) study found that some biomarkers measured at the baseline
were related to the incidence and progression of OA in the knee. Interestingly,
uCTX-II and sCOMP were the most consistent biomarkers associated with the
presence, incidence, and progression of knee OA.
UCTX-II and sCOMP had a positive effect on the presence and progression of
OA in the knee. Both biomarkers showed negative correlation with knee OA. The
authors suggested that the low cartilage and subchondral bone turnover in the
earliest stages of knee OA may explain this second finding [67].
Over the past years, the mechanisms and benefits of inflammatory biomarkers
in the pathogenesis and progression of OA have also been studied. The data from
the Rotterdam study showed that CRP was independently associated with the
incidence and progression of OA, similar to uCTX-II and sCOMP, and CRPM
showed positive correlation to the progression of OA [69].
In a meta-analysis of the knee, hip, and hand OA studies from 1992 to 2012 [70],
no correlation between the pain symptoms of OA and hs-CRP levels was found.
However, radiographic findings showed strong correlation with hs-CRP levels. As
shown in another study, inflammatory macrophages in the joints of knee OA patients
might be a potential source of inflammation that triggers CRP production [71].
Soluble markers of the synovial fluid (SF) and inflammatory macrophages
(CD14 and CD163) were shown to be associated with abundance of active macro-
phages in the knee joint as measured by EC20 SPECT imaging. These soluble
markers were associated with narrowing of the joint space, osteophytes, and sever-
ity of the knee pain [72].
The best known inflammation markers have been confirmed in a study by Attur
et al. [73]. Previously, proinflammatory mediators such as IL-1β, TNF-α, and COX-2
in peripheral blood leukocytes have been shown to identify the patients under risk
for knee OA [74]. In a cohort of symptomatic knee OA patients prospectively
evaluated for 24 months, an increase in the peripheral blood transcripts regarding
11
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the basal levels of IL-1β, TNF-α, and COX-2 was shown to predict the narrowing of
the joint space [73]. In another study assessing the samples taken from symptomatic
knee OA patients under prospective evaluation for 24 months, the authors con-
cluded that the levels of plasma interleukin-1 receptor antagonist (IL-1Ra) were
positively correlated with the severity and progression of knee OA [75].
In addition to the above findings, reduced serum and uncarboxylated matrix Gla
protein (ucMGP) levels were detected in OA patients. The mean serum ucMGP
levels in knee OA patients were significantly lower than the healthy controls and
showed negative correlation with radiographic severity [76].
Mabey et al. reported that the IL-4 and IL-6 levels in OA patients were signifi-
cantly higher than the controls and showed positive correlation with radiographic
severity [77].
In a study conducted on 138 OA patients [78], adipsin (complement factor D),
leptin, adiponectin, resistin, and serpin E1 levels in the serum and cartilage volume
with MRI were measured at the baseline and after 24 months. The elevated levels of
adipsin and leptin were correlated to the increased cartilage volume in the global
knee and medial femur. Adiponectin levels showed negative correlation with the
cartilage volume in the medial compartment and femur. No correlation between
resistin and serpin E1 and cartilage volume was detected.
10. Conclusion
In conclusion, biochemical markers, especially Type II collagen production,
demolition, and synovial tissue markers, are important contributors in the early
diagnosis, treatment, and follow-up of OA. Numerous biochemical markers that can
potentially predict the progression of OA are still under research, but the progress is
slow. For a molecule to qualify as a marker, it must be biologically and methodo-
logically sensitive and specific. COMP, antigenic keratan sulfate, hyaluronan, YKL-
40, Type III collagen N-propeptide, and urine Gly-Gal-Pyd are the most promising
biochemical markers. The only predictor of cartilage loss determined by MR in the
knee OA is sCOMP [79].
Early identification of OA with possible identification of new biochemical bio-
markers with proteomic studies in the future seems possible. More comprehensive
randomized and controlled studies of biomarkers will provide useful information in
early diagnosis, prognosis, and response to treatment in OA.
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